Holen Sie sich die Stockscreener-App
9.45
2.38%
-0.23
Schlusskurs vom Vortag:
$9.68
Offen:
$9.6
24-Stunden-Volumen:
1.35M
Relative Volume:
1.35
Marktkapitalisierung:
$744.37M
Einnahmen:
-
Nettoeinkommen (Verlust:
-
KGV:
-
EPS:
-
Netto-Cashflow:
-
1W Leistung:
-14.71%
1M Leistung:
-29.69%
6M Leistung:
+0.00%
1J Leistung:
+0.00%
1-Tages-Spanne:
$9.32
$9.69
1-Wochen-Bereich:
$9.32
$11.58
52-Wochen-Spanne:
$5.33
$14.69
Niagen Bioscience Inc Stock (NAGE) Company Profile
Firmenname
Niagen Bioscience Inc
Sektor
Branche
Telefon
310-388-6706
Adresse
10900 WILSHIRE BLVD, LOS ANGELES
Vergleichen Sie NAGE mit anderen Aktien
| Aktien | Preis | Marktkapitalisierung | Umsatz | Nettogewinn | Free Cashflow | ENV |
|---|---|---|---|---|---|---|
NAGE
Niagen Bioscience Inc
|
9.45 | 872.77M | 0 | 0 | 0 | 0.00 |
|
VRTX
Vertex Pharmaceuticals Inc
|
470.13 | 119.21B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
560.93 | 59.16B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
325.28 | 40.57B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
571.23 | 34.02B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
295.59 | 29.19B | 3.81B | -644.79M | -669.77M | -6.24 |
Niagen Bioscience Inc Stock (NAGE) Upgrades & Downgrades
| Datum | Aktion | Analytiker | Ratingänderung |
|---|---|---|---|
| 2025-05-27 | Eingeleitet | Canaccord Genuity | Buy |
| 2022-08-16 | Herabstufung | Oppenheimer | Outperform → Perform |
| 2022-08-11 | Herabstufung | B. Riley Securities | Buy → Neutral |
| 2022-03-08 | Eingeleitet | ROTH Capital | Buy |
| 2019-10-16 | Eingeleitet | Oppenheimer | Outperform |
| 2019-02-14 | Eingeleitet | B. Riley FBR | Buy |
| 2017-11-27 | Fortgesetzt | H.C. Wainwright | Buy |
| 2017-09-25 | Eingeleitet | Ladenburg Thalmann | Buy |
| 2017-01-03 | Eingeleitet | Rodman & Renshaw | Buy |
Alle ansehen
Niagen Bioscience Inc Aktie (NAGE) Neueste Nachrichten
What analysts say about Niagen Bioscience Inc. stockFree Consultation - Autocar Professional
What drives Niagen Bioscience Inc. stock priceTurbocharged investment results - Autocar Professional
Niagen Bioscience Inc. Stock Analysis and ForecastFree Stock Market Forecast Reports - jammulinksnews.com
Is Niagen Bioscience Inc. a good long term investmentDouble-digit growth - jammulinksnews.com
Niagen Bioscience Shares Climb Following Exclusive License for Parkinson’s Therapy - MSN
Niagen Bioscience (NASDAQ:NAGE) Shares Down 4%Time to Sell? - MarketBeat
Niagen Bioscience, Inc. (NASDAQ:NAGE) Receives Average Rating of "Buy" from Brokerages - MarketBeat
Analysts Set Niagen Bioscience, Inc. (NASDAQ:NAGE) Target Price at $13.22 - Defense World
How Niagen Bioscience Inc. stock performs during market volatilityROI Driven Alerts - Newser
What makes Niagen Bioscience Inc. stock price move sharplyFree Stock Market Group - Newser
Why Niagen Bioscience Inc. stock attracts strong analyst attentionTop Growth Low Risk Stocks - Newser
Niagen Bioscience shares fall 1.15% intraday after announcing Tru Niagen debut at Equinox Hotel New York. - AInvest
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York | NAGE Stock News - GuruFocus
Niagen Bioscience Announces the Debut of Tru Niagen® and Niagen IV at Equinox Hotel New York - New Castle News
Niagen Bioscience signs exclusive licence deal for PD therapy - Yahoo Finance
Niagen Bioscience Secures Exclusive License to Develop and Commercialize its NAD+ Precursor, Patented Nicotinamide Riboside (Niagen®), as a Potential Parkinson’s Disease Therapy in Agreement with Haukeland University Hospital in Bergen, Norway - BioSpace
Niagen Bioscience (NAGE) Secures Exclusive License Agreement - GuruFocus
Niagen Bio signs license deal with Haukeland University (NAGE) - Seeking Alpha
Niagen Bioscience stock rises on exclusive Parkinson’s treatment license - Investing.com India
Niagen Bioscience secures exclusive rights for Parkinson’s treatment By Investing.com - Investing.com Nigeria
Niagen Bioscience secures exclusive rights for Parkinson’s treatment - Investing.com
Niagen Bioscience stock rises on exclusive Parkinson’s treatment license By Investing.com - Investing.com Nigeria
Niagen Bioscience Secures Exclusive License to Develop and Comme - GuruFocus
Niagen Bioscience (NASDAQ:NAGE) Shares Down 9.5%Should You Sell? - MarketBeat
Niagen Bioscience (NASDAQ:NAGE) Reaches New 12-Month HighHere's Why - MarketBeat
Niagen Bioscience stock hits 52-week high at 14.49 USD - Investing.com
Finanzdaten der Niagen Bioscience Inc-Aktie (NAGE)
Es liegen keine Finanzdaten für Niagen Bioscience Inc (NAGE) vor. Überprüfen Sie andere Aktien für weitere Informationen.
Umsatz
Nettogewinn
Free Cashflow
ENV
0.51%
In Yahoo öffnen
|
In Google öffnen
|
In Finviz öffnen
|
In MarketWatch öffnen
|
Öffnen Sie in EDGAR
|
Offen in Reuters
Kapitalisierung:
|
Volumen (24h):